A rat kidney phenol UDP-glucuronosyltransferase cDNA was used to isolate a human liver phenol UDPglucuronosyltransferase cDNA by screening of a human liver cDNA library in the expression vector Agtll. The 2.4-kilobase cDNA contained an open reading frame of 1593 base pairs coding for a protein of 531 residues. The human liver cDNA was subcloned into the vector pKCRH2. Transfection of this recombinant plasmid into COS-7 cells allowed the expression of a protein of -55 kDa. The enzyme synthesized was a glycoprotein, as indicated by a reduction in molecular mass of :3 kDa after biosynthesis in the presence of tunicamycin. The expressed enzyme rapidly catalyzed the glucuronidation of 1-naphthol, 4-methylumbelliferone, and 4-nitrophenol. The use of a related series of simple phenols provided an outline description of the substituent restrictions imposed upon the phenolic structures accepted as substrates. The glucuronidation of testosterone, androsterone, and estrone was not catalyzed by this cloned UDP-glucuronosyltransferase.
bilirubin UDPGT in Crigler-Najar syndrome (8) have also indicated the existence of different UDPGT isoforms. By using antibodies prepared against purified rat UDPGT antigens, which inhibit several human liver microsomal UDPGT activities, at least five UDPGTs have been detected in human liver microsomes by immunoblot analysis (9, 10) . Human liver microsomal UDPGTs have proved difficult to purify, although two distinct UDPGTs with similar properties have been purified to apparent homogeneity (11) .
The further analysis of the multiplicity, genetic deficiency, regulation, and development of human UDPGTs requires the use of molecular probes for DNA, RNA, and proteins, and these can be obtained by molecular biological techniques without the need for routine supplies of human liver. The previous expression of a cloned rat UDPGT cDNA (12) has been shown to define distinctive substrate specificities avoiding the possibility of very homologous contaminating UDPGTs, which could occur even after the most rigorous purification procedures. Mechanisms of drug transport, glucuronidation, and excretion can also be studied by using the transferases expressed in cells in culture.
In this paper we report the molecular cloning and sequence of a human liver UDPGT cDNA.* Expression of the cDNA in COS-7 cells and the substrate specificity studies indicate that a phenol UDPGT was encoded by this clone and provide evidence of certain structural restrictions imposed on potential substrates.
MATERIALS AND METHODS Materials. Anti-UDPGT serum and anti-epoxide hydrolase (EH) serum were prepared as reported (13) . 32P (17) and used as a hybridization probe to plaque-screen (18) the human liver cDNA library in phage Agtll (16) , at 580C in 6x SSPE (19) . cDNA inserts from the plaque-purified recombinant phage were subcloned into pUC18 and M13mpl8 or -19 (20) for restriction analysis and sequencing by a modified procedure of Sanger's dideoxy method (21, 22) . Human microsomal EH cDNA was cloned in this laboratory (23) .
The full-coding-length cDNA was excised from M13mpl8 with EcoRI, reisolated with HindIII, and subcloned into the HindIII site of the tissue culture expression vector pKCRH2.
Recombinant plasmids were grown in Escherichia coli DH1 and plasmids with cDNAs in the correct orientation with respect to transcription from the simian virus 40 early gene were identified by restriction mapping. Plasmid DNA (40 ug) was used to transfect each semiconfluent dish (150 cm2) of COS cells by calcium phosphate/glycerol shock procedure Abbreviations: UDPGT, UDP-glucuronosyltransferase; EH, epoxide hydrolase. *The sequence reported in this paper is being deposited in the EMBL/GenBank data base (IntelliGenetics, Mountain View, CA, and Eur. Mol. Biol. Lab., Heidelberg) (accession no. J04093).
8381
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (24) or "lipofection" (25) 7.4 with HCl). Cells were harvested and centrifuged at 1500 x g for 5 min. The pellets were resuspended and washed with PBS by centrifugation. The pellet was solubilized with 0.5% deoxycholate, 1% Triton X-100, plus 0.1% sodium dodecyl sulfate (SDS) in 10 mM Tris HCl (pH 7.4) by gentle hand homogenization. The mixture was centrifuged at 16 ,000 x g and the supernatant was incubated with preimmune serum and in sheep anti-rat UDPGT antiserum overnight in ice as described (29) . The final products were analyzed by SDS/PAGE on 7.5% polyacrylamide gels (30) followed by fluorography (31) .
RESULTS AND DISCUSSION
Isolation and Sequencing of cDNA Clones Encoding a Human Phenol UDPGT. Sixteen recombinant plaques were identified after screening 100,000 recombinants of the Agtll human liver cDNA library with the 32P-labeled full-codinglength rat kidney phenol cDNA. The sizes of the cDNA inserts were determined on agarose gels and the largest cDNA (-2.4 kilobases) was further analyzed. The subcloned cDNA insert was restriction-mapped and sequenced according to the strategy indicated in Fig sequence is shown in Fig. 2 . There was an 86-base-pair (bp) 5' noncoding region, a 1593-bp coding sequence, and a 754-bp 3' noncoding region containing two possible polyadenylylation site (AATAAA) 14 (Fig. 2) . This assignment was based on the homology of the initiation codon flanking sequence to the consensus start site (32) and by analogy with the rat phenol UDPGT sequence (33) . The amino acid sequence ofthis human transferase shows 76% sequence identity to the phenol UDPGTs isolated from rat liver (33) and kidney (D.H. and B.B., unpublished work), but only showed 44% identity with human UDPGT H25 (9) , which appears to catalyze the glucuronidation of 6a-hydroxy bile acids (S. M.R.J., R. Wooster, and B.B., unpublished work). These findings suggest that the two human transferases are members of subfamilies ofthis gene superfamily. The similarity between the two human sequences was concentrated toward the C terminus, where a potential UDP-glucuronic acid binding site (>65% identity) may be located within residues 300-515, which includes a predicted membrane-anchor sequence (Fig.  3b) . However, comparison of the hydrophobicity plots of the two human UDPGT sequences (Fig. 3a) predicted many common folding patterns despite the apparent lack of overall homology. Expression ofPhenol UDPGT Protein. The cDNA HLUGP1 was subcloned into the expression vector pKCRH2 where transcription was driven by the simian virus 40 4, lanes 3-7, shows the specific expression of a phenol UDPGT (55 kDa). This protein is a similar size to the two phenol UDPGTs purified from human liver (11) . The tunicamycin treatment was only partially effective in inhibiting glycosylation of the expressed UDPGT isoenzyme but the mobility of some UDPGTs was increased in the presence of tunicamycin indicating that this protein was glycosylated. Inhibition of glycosylation reduced the size of the protein to 52 kDa. These proteins were not immunoprecipitable from COS cells transfected with the vector alone (Fig. 4) .
Expression and Substrate Specificity of Phenol UDPGT. Results from the expression of enzyme activities after transfection of COS-7 cells with vectors containing HLUGP1 cDNA or no inserts are shown in Table 1 and Fig. 5 . The data in Fig. 5 illustrate the assay methodology and provide a visual impression of the results. High rates of UDPGT activity toward 1-naphthol and 4-methylumbelliferone were observed. The substrate specificity with a series of closely related phenols was further investigated to provide indications of the chemical structures accepted into the active site of the enzyme. Phenol was a poor substrate, whereas substituents at position 4 such as -NO2, methyl, or ethyl groups were good substrates. The bulkier 4-alkyl-substituted phenols, 4- propylphenol, and 4-butylphenol were again poor substrates, indicating a size and/or planarity restriction in access of these substrates to the active site of the enzyme as was suggested (35) from studies ofthe rat fetal liver UDPGT. It would appear that the enzyme in fetal rat liver, the cloned kidney phenol UDPGT (unpublished work), and the cloned human liver phenol UDPGT exhibit a remarkably similar substrate specificity, although the cloned enzymes are only 76% similar in Irshaid and Tephly (11) have purified two human liver UDPGTs that exhibited very similar substrate specificity and that glucuronidate 4-nitrophenol and 4-methylumbelliferone. We were unable to use the discriminating substrate 4-aminobiphenyl (11) to assay the cloned expressed human phenol UDPGT, because use of this carcinogenic compound is prohibited in the U.K. The expressed phenol UDPGT catalyzed the glucuronidation of 4-nitrophenol 1.4 times faster than 4-methylumbelliferone, but not the glucuronidation of estriol, suggesting that this gene product may be the same as the purified human phenol UDPGT(pI 6.2) (11) .
Kinetic analysis of phenol glucuronidation also suggests the existence of more than one UDPGT involved in formation of 1-naphthol and 4-methylumbelliferone glucuronides (36) . The data presented here (Table 1) , where the expressed enzyme was compared with the transferases present in human liver microsomes, would predict that glucuronidation of 4-methylumbelliferone involved possibly two or three microsomal UDPGTs.
The cloned expressed human enzyme did not catalyze the glucuronidation of (-)-morphine, phenolphthalein, or 4-hydroxybiphenyl. Further, the expressed human phenol UDPGT did not catalyze the glucuronidation of endogenous compounds, testosterone, androsterone, and estrone in agreement with the results obtained from purification studies (11) . All of these substrates were rapidly glucuronidated by rat liver microsomes (data not shown).
Several other human liver UDPGT cDNAs have been obtained; some have close homology with HLUGP1. Expression of these cDNAs in cell cultures will allow an accurate assessment ofthe substrate of human UDPGTs in whole cells and their ability to catalyze drug glucuronidation. Preliminary drug screening and improved drug design will be possible by using these systems, although, as only a small proportion of the cells transiently express the transfected cDNA, the establishment of stable cell lines where every cell expresses the cloned UDPGT will greatly improve the effectiveness of this technique.
